Samsung Bioepis wins APAC 'Company of the Year' for 3rd straight year at 2024 Global Generics & Biosimilars Awards

Samsung Bioepis has once again been announced as the Asia-Pacific Company of the Year at the 2024 Global Generics & Biosimilars Awards, held in Milan, Italy, last Wednesday (local time). This marks the company's third consecutive win in this category, following awards in 2022 and 2023.

The Global Generics & Biosimilars Awards, organized by pharmaceutical industry intelligence provider Citeline, recognize exceptional achievements in the generics and biosimilars industry worldwide.

Samsung Bioepis was acknowledged for its significant advancements in research, development, and commercialization over the past year.

Samsung Bioepis achieved several milestones in 2024, including the approval of its Stelara biosimilar, Pyzchiva in both Europe (April) and the U.S. (June).

The company’s partner Sandoz subsequently launched Pyzchiva in Europe in July. Also, Biogen, Samsung Bioepis global partner for its Eylea biosimilar, Opuviz, received approval for the biosimilar from the FDA in May, and received a positive opinion from the European Medicines Agency (EMA) in September for the same product.

The company gained U.S. approval for its Soliris biosimilar, Epysqli, in July.

Samsung Bioepis currently boasts a robust portfolio of 11 biosimilar products and pipeline candidates. The company has received approval for nine products in the fields of immunology, oncology, ophthalmology, hematology, and nephrology.